NanoVibronix Inc (NAOV)

[subslover]

Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal
UroShield Cited as Effective in Preventing CAUTIs and Blockages, Having a Major Impact on Quality of Life and Reducing Healthcare Resource Costs

ELMSFORD, N.Y.--(BUSINESS WIRE)-- NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced that an independent health service study of its UroShield® is published in The Australian and New Zealand Continence Journal.

The study highlights UroShield’s effectiveness in preventing catheter-associated urinary tract infections (CAUTIs) and recommends its adoption for appropriate patients with indwelling urinary catheters (IUCs). Researchers found that patients using UroShield experienced an 86% reduction in UTI incidence; 70% reduction in catheter blockages; 82.8% less bladder irrigations performed and 52.3% less catheter changes. The clinicians reported improved overall catheter comfort and a reduction in the need for catheter-related interventions.

Brian Murphy, CEO of NanoVibronix, Inc., commented, “This study underscores the benefits of UroShield in enhancing patient care by reducing CAUTI incidence and catheter blockages, minimizing catheter complications and improving overall comfort. Notably, researchers found that UroShield required less nursing time, which eased workload demands and resulted in measurable cost savings for the healthcare provider."

From the article:

“The introduction of the UroShield® device within a New Zealand District Nursing Service significantly improved the lives of patients with indwelling urinary catheters. This Quality Improvement project demonstrated a reduction in catheter-associated urinary tract infections and blockages, leading to fewer interventions and enhanced patient comfort. The project highlighted how UroShield® can reduce healthcare costs and improve the quality of life for patients, suggesting its potential for use in similar healthcare settings.”

“The final cost analysis has shown a significant reduction in resource expenditure due to a combination of less interventions, and less urgent call outs. The UroShield® proved to have a 63.5% reduction in resource cost over the 5 months of the project.”

The complete article is available at https://www.publish.csiro.au/CJ/pdf/CJ24043.

About NanoVibronix, Inc.

NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Tyler, Texas, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surf